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The vertebrate protein SAMHD1 is highly unusual in having roles
in cellular metabolic regulation, antiviral restriction, and regulation
of innate immunity. Its deoxynucleoside triphosphohydrolase activ-
ity regulates cellular dNTP concentration, reducing levels below
those required by lentiviruses and other viruses to replicate. To
counter this threat, some primate lentiviruses encode accessory
proteins that bind SAMHD1 and induce its degradation; in turn,
positive diversifying selection has been observed in regions bound
by these lentiviral proteins, suggesting that primate SAMHD1 has
coevolved to evade these countermeasures. Moreover, deleterious
polymorphisms in human SAMHD1 are associated with autoim-
mune disease linked to uncontrolled DNA synthesis of endogenous
retroelements. Little is known about how evolutionary pressures affect
these different SAMHD1 functions. Here, we examine the deeper
history of these interactions by testing whether evolutionary signa-
tures in SAMHD1 extend to other mammalian groups and exploring
the molecular basis of this coevolution. Using codon-based likeli-
hood models, we find positive selection in SAMHD1 within each
mammal lineage for which sequence data are available. We observe
positive selection at sites clustered around T592, a residue that is
phosphorylated to regulate SAMHD1 activity. We verify experi-
mentally that mutations within this cluster affect catalytic rate
and lentiviral restriction, suggesting that virus–host coevolution
has required adaptations of enzymatic function. Thus, persistent
positive selection may have involved the adaptation of SAMHD1
regulation to balance antiviral, metabolic, and innate immunity
functions.
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The parasitic nature of their lifestyle brings viruses into evo-lutionary conflict with the immune systems of their hosts.
Vertebrates have evolved an arsenal of innate immunity pro-
teins, called restriction factors, that target conserved features of
virus replication cycles, while some viruses, in turn, have evolved
means of neutralizing (or “antagonizing”) them, often by mecha-
nisms involving direct protein–protein interactions (1, 2). This
leads to an evolutionary “arms race” as the restriction factor
undergoes rapid evolution to alter the interaction interface and
prevent recognition by a viral antagonist, while the antagonist
similarly evolves to restore binding.
SAMHD1 (sterile alpha motif and histidine-aspartic acid
domain-containing protein 1) is a restriction factor of several
groups of retroviruses and DNA viruses, including lentiviruses
[namely, HIV, simian immunodeficiency virus (SIV), and feline
immunodeficiency virus (FIV)], vaccinia, herpes simplex 1, and
hepatitis B viruses (3–10). Its deoxynucleoside triphosphohydrolase
(dNTP-tpase) activity suppresses viral replication by hydrolyzing
dNTPs, reducing the intracellular concentration of substrates re-
quired for viral DNA production (11, 12). HIV-2 and related SIVs
counter SAMHD1 by expressing the accessory protein Vpx that
recruits SAMHD1 to DCAF1, targeting it for degradation through
the cellular Cullin-4–based E3 ubiquitin ligase machinery (3, 4, 13–
16). Some other primate lentiviruses use the related Vpr protein to
fulfill the same role (17), although HIV-1 Vpr does not have the
equivalent function. Vpx/Vpr from different lentivirus lineages
target different regions of SAMHD1, recognizing either the N or C
termini (18). Evolutionary analyses of primate SAMHD1 have
shown that positive diversifying selection has occurred in these
2 different binding regions, suggesting an evolutionary arms race
between viruses and SAMHD1 in primates (17, 19). SAMHD1
antagonism by primate lentiviruses is often strikingly host-specific,
including adaptation to dominant SAMHD1 alleles within species,
suggesting that the evolutionary conflict has led to highly intricate
coevolution (20).
In addition to its antiviral function, SAMHD1 also maintains
the fine balance of intracellular dNTP levels that allows pro-
gression of the cell cycle (21), while preventing the accumulation
of endogenous nucleic acids (22). The enzyme’s activity is reg-
ulated by conversion between the catalytically active tetrameric
state and the weakly active monomeric or dimeric forms (23).
Tetramers are favored in the presence of SAMHD1’s allosteric
regulators, dNTP and GTP/dGTP molecules (24, 25), while
phosphorylation of threonine residue 592 (T592), located near
the C terminus, reduces the stability of the SAMHD1 tetramer,
favoring the monomeric state. In both primates and mice,
phosphorylation is mediated by CDKs 1/2 complexed with cyclin
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A2, suggesting that this mechanism of regulation is conserved
among mammals (26–30).
Two crucial features of this molecular arms race remain un-
clear. First, since SAMHD1 is found throughout vertebrates, and
DNA-producing viruses infect all domains of life, how widespread
is the evolutionary conflict between viruses and SAMHD1 in other
taxa? Second, how has SAMHD1 responded to selective pressure
from its dual roles in virus restriction and dNTP regulation?
To address these questions, we applied codon-based likelihood
models to a large set of SAMHD1 sequences from a diverse range
of mammals. We found evidence of positive diversifying selection
in every group of mammals for which data are available, indicating
a pathogen–SAMHD1 arms race extending throughout mamma-
lian evolution. Strikingly, many of the sites under positive selection
cluster around T592, indicating positive selection acting on sites
that modulate SAMHD1 phosphorylation, tetramerization, and,
therefore, enzymatic activation. We show that replacing amino
acids at some of these sites with residues observed in other
mammal species reduces dNTP-tpase activity and can reduce
HIV-1 restriction in cell culture. SAMHD1 has therefore experi-
enced an unusual combination of selective constraints as selection
pressure imposed by viruses interacted with the need to maintain,
regulate, and adjust enzymatic activity.
Results
Positive Selection in Mammals.To investigate the history of SAMHD1
during mammalian evolution, we compiled a dataset of 120 publicly
available mammalian SAMHD1 coding sequences (SI Appendix,
Table S1), including 5 well-represented clades: the Primates (n =
55), the Glires (rodents, rabbits, and hares; n = 16), the Cetar-
tiodactyla (whales and even-toed ungulates; n = 18), the Carnivora
(cats, dogs, bears, etc.; n = 8), and the Chiroptera (bats; n = 6). A
phylogenetic tree estimated from these gene sequences by maxi-
mum likelihood was mostly concordant with the reported mam-
malian species phylogeny (31), and the majority of nodes had
support values above 70% (SI Appendix, Fig. S1).
Using the site-specific selection models implemented in
PAML (32–34), we found that the likelihood-ratio test supported
the presence of positive selection in mammalian SAMHD1 (P =
4 × 10−90; SI Appendix, Table S2), and 36 sites were identified as
under positive selection (posterior probability > 0.95; Fig. 1A
and SI Appendix, Table S3). We identified most of the same set
of sites as under positive selection when repeating the analysis
using 3 alternative tree topologies (SI Appendix, Tables S2 and
S4), indicating that the result is not sensitive to possible minor
inaccuracies in the estimated phylogeny topology.
As positive selection has been detected in primate SAMHD1
(17, 19), we sought to test whether this signature of a molecular
arms race was specific to primates by repeating the analysis with
the primate clade removed. Again, we found statistical support
for positive selection (P = 3 × 10−66), and 31 sites were identified
as under positive selection in nonprimate mammals (Fig. 1B and
SI Appendix, Table S3). Of these, 29 had also been identified in
the analysis of the all-mammals dataset (SI Appendix, Fig. S2A).
These results indicate that positive selection is not confined to
primate SAMHD1, but has also occurred in other mammals.
Fig. 1. Codon sites under positive selection in mammalian SAMHD1 identified in this and previous studies. Panels represent the linear sequence, and vertical
bars mark sites where the posterior probability of positive selection (Bayes empirical Bayes calculation) is greater than 0.95 (bar height is not meaningful). In
parentheses are the total numbers of sites thus identified. Site numbering is based on the human sequence. At the top is a cartoon showing
SAMHD1 sequence features. NLS, nuclear localization signal; P, phosphorylation site T592. Shaded regions correspond to the N-terminal Vpx/Vpr binding site
(yellow), C-terminal Vpx/Vpr binding site (red), and region around the T592 phosphorylation site (blue), determined with reference to SAMHD1 crystal
structures. Asterisks indicate where there is statistically significant clustering of sites identified as under positive selection in these sequence regions (SI
Appendix, Table S5). *P < 0.05; **P < 0.01; ***P < 0.001. Note that the 2 sections comprising the phosphorylation region (blue) are treated as a single region.
(A) Results from analysis of all mammals with PAML model M2a. (B) Similar analysis of mammals with primates excluded. (C and D) Published results of Lim
et al. (17) and Laguette et al. (19), both from analyses of primate SAMHD1 with PAML model M8. (E–J) Sites identified in mammal subgroups, model M8.
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Positive Selection in Mammal Subgroups. We next determined
whether the positive-selection signal was due to specific groups
within mammals by repeating the analyses with each of the well-
represented subclades. We also performed the analysis on a 6th
group comprising the other species not belonging to a well-
represented monophyletic set (n = 17), hereafter called “Other
Mammals.” We observed evidence for positive selection in all of
these subgroups. The identified sites for each subgroup were
distributed in similar regions as sites found in our analysis of all
mammals (Fig. 1 and SI Appendix, Table S3), although many of
the identified sites were specific to a particular clade (SI Ap-
pendix, Fig. S2B). The Chiroptera (bats) had the greatest pre-
ponderance of sites, with 26 identified, while the Carnivora
(dogs, cats, etc.) had the fewest sites, 4, all in the C-terminal
region. These data indicate that positive selection has occurred
in multiple groups throughout mammalian evolution. Only
5 sites were identified in the Primates (Fig. 1E), 4 of which were
found by Laguette et al. (19) in their analyses of primate
SAMHD1 using the same PAML models, while none of these
were identified by Lim et al. (17) in a similar analysis, both
presumably because of the larger number of sequences now
available to us (35). Several of the sites reported by these authors
as having posterior probabilities for positive selection above the
conventional 0.95 threshold nonetheless had probabilities >0.90 in
our analysis (SI Appendix, Fig. S3).
Positive Selection at Vpx/Vpr Binding Regions. We next examined
whether the sites under positive selection in mammalian
SAMHD1 are in the 2 distinct regions of the protein targeted by
known SAMHD1 antagonists. We therefore mapped the iden-
tified sites onto crystal structures of primate SAMHD1 bound to
lentiviral Vpx/Vpr proteins. We found 11 sites under positive
selection in all mammals within the C-terminal Vpx/Vpr binding
region (sites 606–626; ref. 36; SI Appendix, Fig. S4A), 5 of which
have side chains directly contacting Vpx residues (sites 609; 610;
611; 618; and 622). By calculating the probability that 11 of
36 identified sites should fall in this binding region comprising
20 sites of a total 626 sites by chance (Methods), we found the
concentration of sites identified as under positive selection in
this region to be highly significant (P < 10−6). All but 1 of these
Vpx-contacting sites (site 609) were also identified when primate
sequences were excluded from the analysis, and the clustering of
sites under positive selection in this region (calculated by the
same approach) was also significant for sites identified in Glires,
Cetartiodactyla, Chiroptera, and Other Mammals alone. We also
identified several sites (32; 55; 57; 60; and 63) under positive
selection across mammals in the N-terminal Vpx/Vpr binding
region (sites 1–69; ref. 37; SI Appendix, Fig. S4B), where positive
selection was similarly identified by Laguette et al. (19) and Lim
et al. (17). This included sites in direct contact with Vpx, though
this clustering was not statistically significant. Again, all but 1 of
these (site 63) were also identified with primate sequences ex-
cluded. This overlap of sites under positive selection in mammals
with regions bound by lentiviral Vpx/Vpr proteins, particularly
the C-terminal binding site, suggests the existence of factors
expressed by other viruses that may target similar regions of
SAMHD1 in species other than primates.
Positive Selection in C-Terminal Region Around Phosphorylation Site
T592. We observed clustering of sites under positive selection in
2 stretches of the C-terminal region (sites 456–502 and 550–599)
that fold together to form a domain containing the phosphory-
lation site, T592 (Figs. 1 and 2). This clustering was statistically
significant (P < 0.05) in all mammals, the Cetartiodactyla
(whales and even-toed ungulates), the Chiroptera (bats), and the
Other Mammals (SI Appendix, Table S5). None of the identified
sites were located at the interface between SAMHD1 monomers
or at the dNTP-binding catalytic or allosteric sites (Fig. 2A). The
positioning of sites under positive selection in the region around
the phosphorylation site therefore suggests that rapid evolution
involved modulation of SAMHD1 function.
Point Mutations at C-Terminal Sites under Positive Selection Affect
SAMHD1 Function.Given the interesting distribution of sites under
positive selection, we next investigated the sensitivity of SAMHD1
structure, function, and regulation to replacements at positions
under positive selection surrounding the phosphorylation site.
We identified 4 sites of particular interest due to their structural
context, proximity to T592, and the distribution of residues seen
in different species (Fig. 2, yellow). Site 566 (arginine in humans)
has undergone many physicochemically nonconservative substi-
tutions to residues greatly varying in size, such as glycine, glu-
tamine, and histidine, despite being mostly buried (SI Appendix,
Fig. S5). Site 574 (alanine in humans) is almost entirely buried in
the C-terminal region, yet residues with much larger side chains
and contrasting physicochemical properties were observed in
other species, including leucine, phenylalanine, and serine (SI
Appendix, Fig. S6). Sites 594 and 596 (glutamine and lysine in
humans, respectively) are both very close to T592 (Fig. 2B), and,
again, chemically diverse residues were observed at these posi-
tions (SI Appendix, Figs. S7 and S8). The amino acid at site
596 marks the divergence of New World monkeys (negatively
charged aspartate) from Old World monkeys and apes (posi-
tively charged lysine). To investigate whether these residues are
likely to have the same structural context across species, we used
homology modeling to predict animal SAMHD1 protein struc-
tures (38). Comparing each animal model structure to the hu-
man structure, the minimum root mean square deviation (rmsd)
of atoms was below 0.4 Å, and corresponding Z-scores with re-
spect to random structure alignments were all above 50, in-
dicating very close structural similarity (SI Appendix, Table S6;
ref. 39).
We then selected 1 or more residues that had been observed in
multiple animal species at these 4 sites and introduced them
into a human SAMHD1 background to test effects on function.
Further homology-modeling experiments had shown that these
residues had almost identical position and orientation when
comparing mutant human SAMHD1 model structures and ani-
mal model structures for which these residues are wild type
(WT), as measured by rmsd between atoms in their side chains;
this suggested that the mutant residues in the human background
accurately recapitulate their situation in their respective WT
animal SAMHD1 structures (SI Appendix, Table S7 and Fig. S9).
WT and mutant SAMHD1 constructs were expressed in Escherichia
coli, and the activator and substrate dependence of tetramerization
of purified proteins was analyzed by size-exclusion chromatography
coupled to multiangle laser light scattering (SEC-MALLS). Each
mutant was tested for tetramerization of the apo protein and with
the addition of either GTP activator alone or GTP and additional
dATP substrate. As with WT human SAMHD1, these experi-
ments showed that no human SAMHD1 mutants tetramerize in
the apo form or with the addition of GTP alone (SI Appendix, Fig.
S10). On incubation with GTP and substrate dATP, all of the
mutants underwent tetramerization with similar efficiency to WT,
suggesting that they were not positively selected for this purpose
(SI Appendix, Fig. S11). The degrees of phosphorylation of these
variants were examined by Western blot using phospho-specific
SAMHD1 antibodies (SI Appendix, Fig. S12). Variants Q594L
and Q594R showed reduced signal relative to total SAMHD1
levels, suggesting that at least some positively selected sites do
impinge on phosphorylation; however, differential binding affinity
of the antibody for the mutated sites cannot be ruled out. Overall,
introduction of these mutations did not seem to alter the protein
expression levels greatly (SI Appendix, Fig. S12).
We next assessed the triphosphohydrolase activities of the
purified mutant enzymes. All SAMHD1 mutants had reduced (up









to 2.5-fold) steady-state catalytic rates relative to WT, potentially
due to a mismatch between the new residue and the human
background sequence, but enzymatic activity was not severely
disrupted (Fig. 3 A and B). The greatest effect was with mutant
K596D, which, as mentioned above, marks the distinction between
Old and New World primates (SI Appendix, Fig. S8). All mutants
had similar KM values to the WT, with mutations causing both
increases and decreases in this parameter. One mutant, K596M,
had a 3-fold reduction in KM, suggesting significantly enhanced
substrate binding.
We then assessed the effect of changes at these sites under
positive selection on the ability of SAMHD1 to restrict HIV-
1 infection, measured in differentiated U937 cells using our
previously described 2-color flow-cytometry HIV-1 restriction
assay (23, 40). HIV-1 restriction was not ablated in any of the
mutants tested, but appeared less efficient for several mutants,
consistent with their observed reduction in enzymatic activity
(Fig. 3C). Of note, a few variants (R566Q, Q594L, and Q596P)
restricted HIV-1 infection as efficiently as WT, despite some
reduction of enzymatic activity. We expanded our analysis to
other lentiviruses, equine infectious anemia virus (EIAV) and
FIV, comparing the effects of substitutions A574L (found in
both horse and cat), Q594R (cat), Q594L (horse) (SI Appendix,
Figs. S6 and S7), and WT human SAMHD1 on virus restriction
(Fig. 3 D and E). Notably, variants found in cat conferred
stronger restriction against FIV and EIAV than HIV-1, whereas
the horse variant was relatively weaker, which paralleled their
enzymatic activity, with Q594L being rather less active than
A574L or Q594R (Fig. 3 A and B). Interestingly, the reverse was
also true, as Q594L conferred strong restriction of HIV-1, but
weaker EIAV/FIV restriction. Taken together, these results
demonstrate that positively selected sites around T592 modulate
enzyme activity, lentiviral restriction, and phosphorylation and
provide insights into SAMHD1 regulation and evolution.
Discussion
Viruses impose a significant burden upon their hosts, forcing
them into persistent evolutionary conflict. Host antiviral re-
sponses must be carefully modulated, however, to prevent self-
damage or dysregulation of pathways critical for cell homeosta-
sis. There is evidence that such modulation can be achieved by
controlling levels of transcription of innate immunity genes (41),
but it has been unclear whether regulation of the activity of innate
immunity proteins is also important. By investigating the deep
evolutionary history of the innate immune protein SAMHD1, our
results suggest that this mechanismmight indeed be important and
afford appropriate modulation.
To date, SAMHD1 evolution has been closely studied in pri-
mate lentiviruses and their hosts, where the characteristic sig-
natures of positive diversifying selection have been observed,
specifically at the N- and C-terminal regions that interact with
Vpr/Vpx viral proteins (17, 19). It has remained unclear whether
this coevolution has been restricted to primates and whether the
activity of SAMHD1 might be modulated by the host in response
to pathogens. We have found that positive selection in SAMHD1
is not restricted to primates, but rather has been pervasive
throughout mammalian evolution and can be observed in every
mammal group for which data are available (Fig. 1). This reflects
Fig. 2. Sites identified as under positive selection in mammalian SAMHD1, shown on a published crystal structure (Protein Data Bank ID code 4TNP; ref. 25;
residues 114–276 and 282–599). (A) Human SAMHD1 tetramer with foreground monomer shown as cyan cylindrical-helix cartoon and background monomers
shown as colored surface representations. The 15 sites both under positive selection and present in this structure have their α-carbons shown as orange or
yellow spheres, where yellow indicates sites in the C-terminal region chosen for point mutation experiments; threonine 592 is similarly shown and colored red.
dNTP molecules bound in the foreground monomer are shown as red sticks. (B) Enlarged view of the C-terminal region, with foreground monomer shown as a
plain cartoon, all atoms of sites under positive selection shown by surface representation, and background monomers as translucent surfaces. Highlighted
sites are annotated with human sequence numbering, and site colors are as in A. (B, Left) Site 566 is obscured by site 575. (B, Right) Sites 574 and 594 are
obscured by sites 575 and 486, respectively.
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either widespread similar adaptation to recent pathogens in a
wide range of mammals or, perhaps more likely, an ancient and
ongoing battle between the mammalian innate immune system
and viruses, potentially involving other restriction factors and
taxonomic groups.
We found that regions of SAMHD1 are under positive se-
lection in multiple mammal groups, such as the C-terminal Vpx/
Vpr binding site, which is under positive selection in Glires,
Cetartiodactyla, Chiroptera, and Other Mammals (Fig. 1 and SI
Appendix, Fig. S4). The surfaces of primate SAMHD1 bound by
Vpx/Vpr appear to vary and even fluctuate throughout evolu-
tionary time (18), but the density of sites identified in this region
suggests that viral antagonists in other species may also target
this region. The signatures of positive selection in mammalian
SAMHD1 may represent both ongoing evolutionary conflict and
a record of past battles with viruses now extinct.
Several classes of DNA-producing viruses are restricted in the
presence of SAMHD1 (3–10), suggesting that many diverse an-
imal viruses have an evolutionary incentive to overcome its ef-
fects. SAMHD1 sensitivity extends to FIV and EIAV, although
there is no evidence of SAMHD1 antagonism by these or other
lentiviruses, suggesting that, like HIV-1, their replication strat-
egies do not require it (10). Nonetheless, ancient endogenous
retrovirus sequences have been found in diverse species genomes
(42), indicating that retroviruses have coevolved with animals
and their restriction factors throughout metazoan evolution and
may have imposed selective pressure on their hosts’ SAMHD1.
We identified a significant clustering of sites under positive
selection in the domain containing the phosphorylation site T592,
in mammals in general as well as in Cetartiodactyla, Chiroptera,
and Other Mammals. Replacing human SAMHD1 residues at
sites under positive selection in this domain with those found in
other species—thereby mimicking possible residue substitutions
due to positive selection—modestly enhanced tetramerization and
substrate binding (KM), but reduced the catalytic rate (kcat) (SI
Appendix, Fig. S11 and Fig. 3 A and B). In the case of the Q594L
and Q594R variants, SAMHD1 phosphorylation also appeared to
be reduced (SI Appendix, Fig. S12). Several of the mutations that
decreased enzymatic activity also reduced restriction of HIV-1
(Fig. 3 A–C), demonstrating that sites distant from the active
site and under positive selection have important influence on
SAMHD1 function. Furthermore, we observed that substitutions
normally found in cat and horse resulted in loss of anti–HIV-
1 activity, but maintained restriction of FIV and EIAV, suggesting
changes in SAMHD1 antiviral specificity over evolutionary time.
These results suggest that positive selection in the regions we
observed involves the modulation of SAMHD1’s activity, which
might be differentially adapted in different species, perhaps due to
the different biological properties of reverse transcriptase (RT)
from these lentiviruses (43, 44). More generally, adaptation to
each host’s range of pathogens may therefore have driven the
widespread positive selection we observe.
There is an interesting parallel with the IFN-induced trans-
membrane 3 protein (IFITM3), which restricts diverse enveloped
viruses. Several posttranslational modifications are determined
by IFITM3’s N terminus, and replacing residues here with those
found in nonhuman primate orthologs resulted in opposite ef-
fects on restriction of different viruses, similarly suggesting a
trade-off in viral specificity (45). Meanwhile, SAMHD1 is in
contrast with the rodent transferrin receptor (TfR1), which has
undergone positive selection in regions bound by viruses to
mediate cell entry: Mutations at these positions disrupt TfR1-
dependent virus entry, but without influencing TfR1’s core
functions involved with iron transport, suggesting effective sepa-
ration between selection pressures to avoid pathogen interaction
and retain biological activity (46).
Fig. 3. Activities of SAMHD1 positive selection point mutants. (A) Steady-state kinetics of triphosphohydrolase activity of human SAMHD1 WT and point
mutants. Plots show the concentration dependence of the rate of SAMHD1 TTP hydrolysis in the presence of 0.2 mM GTP activator. The error bars are the SEM
from triplicate measurements. (B) Kinetic parameters kcat and KM obtained from Michaelis–Menten analysis of data in A. Error bars are SEM from triplicate
measurements. (C) Anti–HIV-1 restriction activity of human SAMHD1 WT and point mutants. The bars show the infection ratio of differentiated U937 cells
expressing each variant with respect to an untransduced control. HD is the negative control human SAMHD1 active-site knockout mutant HD206/207AA. Error
bars are the SEM from n = 3 or n = 4 measurements; asterisks indicate statistically significant difference fromWT measured by Student’s t test and controlling
false discovery rate by the Benjamini–Hochberg method. *P < 0.05; **P < 0.01; ***P < 0.001. (D) Anti-FIV restriction activity, as in C. (E) Anti-EIAV restriction
activity, as in C.









One possible explanation is positive diversifying selection on
SAMHD1’s function as a dNTP regulator, independent of its
role as a restriction factor. However, it is not clear why an en-
zyme fulfilling an important homeostatic function would be un-
der diversifying selection, and, moreover, there is no known
precedent for diversifying selection to be associated with enzyme
activity/regulation. Alternatively, substitutions driven by selec-
tion pressure from viruses might impact SAMHD1 enzymatic
activity, resulting in selection for compensatory substitutions.
The surface surrounding T592 may itself constitute an interac-
tion interface, meaning that positive selection in this domain has
occurred to disrupt interaction with viral proteins. However, the
sites identified as under positive selection do not form an obvi-
ous binding surface, since some are buried. A third possibility is
that SAMHD1 regulation is directly involved in the virus–host
evolutionary conflict, adapting catalytic efficiency or propensity
for (de)phosphorylation to regulate antiviral potency. For in-
stance, sites 618 and 619, which were identified as under positive
selection in mammals, nonprimates, and individually in Carniv-
ora (site 618) and Chiroptera (site 619), have been implicated in
binding with cyclin A2, an interaction responsible for the phos-
phorylation of SAMHD1 T592 (28).
In this study, we have found evidence of an arms race between
viruses and their hosts of a significantly larger scale than pre-
viously realized. Far from being limited to primates, we have
found that positive selection has occurred throughout the evo-
lution of SAMHD1 in mammals, most likely due to selection
pressure applied by modern or extinct DNA-producing viruses.
Significantly, we have found evidence that this adaptation can
involve modulation of a host protein’s function. This suggests a
model in which SAMHD1 is under selective constraints to both
conserve its metabolic and antiviral functions while continually
adapting to pressures imposed by viruses. This principle of bal-
ancing function conservation with continual adaptation is likely
to apply to other innate immunity components, as they adapt to
manage the cost of evolutionary conflict.
Methods
Licensing for Human or Animal Materials. This work involved no experiments
using human or animal materials.
Sequence Data and Alignment. Mammalian SAMHD1 DNA sequences were
collected by using NCBI BLAST (blastn algorithm) with human SAMHD1
coding sequence (accession no. NM_015474.3) as the query. Mostly, these
were predicted mRNA sequences originating from automated analysis of
mammal genome sequences, while the majority of primate sequences
originated from previous SAMHD1 studies (17, 19). Where more than 1 se-
quence was available from a single species (usually predicted transcript
variants), sequences most closely matching the human sequence were se-
lected. The sequence for Tasmanian devil (Sarcophilus harrisii) was found to
be divided into 2 sequence records (accession nos. XM_003758997.2 and
XM_012553363.1); these were concatenated to give a full-length sequence.
Preliminary phylogenetic analysis including nonmammal taxa found the
platypus (Ornithorhynchus anatinus) sequence incorrectly positioned outside
of the mammalian clade; this was therefore excluded from subsequent
analysis. The list of species and accession numbers for sequences used are
listed in SI Appendix, Table S1. Sequences that were <70% of the length of
the human SAMHD1 sequence were excluded.
The nucleotide coding sequences were initially aligned as translated
protein by usingMUSCLE [Version 3.8.31; ref. 47, as implemented in SEAVIEW
(Version 4.4.0); ref. 48] and then further edited manually, with a highly
conservative approach: Sections within sequences which could not be
aligned with high confidence were masked, such that they would be treated
as missing data (equivalent to alignment gaps) by phylogenetics tools.
Alignment columns containing no data (exclusively gaps or masked codons)
in 20% of sequences were removed.
Phylogeny Estimation. A phylogenetic tree was estimated by maximum
likelihood using RAxML (Version 7.7.2; refs. 49 and 50) with the general time-
reversible substitution model and gamma-distributed rate heterogeneity.
Confidence in the tree topology was assessed by estimating trees from 1,000
nonparametric bootstrap samples (51). In repeating selection analyses with
alternative tree topologies, we used 3 of the nonparametric bootstrap trees
generated by RAxML that had independent maximum parsimony trees as initial
estimates. Tree figures were produced by using FigTree (Version 1.3.1) (52).
Selection Analysis. Selection analyses were performed by using the codeml
program of the PAML package (Version 4.7a; ref. 34). We used the site-
specific tests of positive selection M1a/M2a (32) and M7/M8 (33). For the
large all-mammals dataset, the more complex M8 model was unable to
converge, and for mammal subgroups, sites identified with M2a were almost
always subsets of those identified with M8.
To reduce the risk of the log-likelihood optimization reaching a local
optimum, all program runs were performed 5 times with different initial
parameters for the transition/transversion ratio (κ) and dN/dS ratio (ω): 0.1, 1,
and 10. Tree branch lengths were first optimized with codeml’s model
0 (which allows a single ω value) with the corresponding initial parameter
values, and these branch lengths were used as starting values in subsequent
analyses with more complex models. Codon stationary frequencies were
estimated by using the F1x4 model by default, but F3x4 was used if opti-
mization difficulties were encountered with F1x4 (null and alternative
models were always compared by using consistent codon frequency models;
SI Appendix, Table S2).
Statistical justification for the alternative model was assessed by using the
likelihood-ratio test, using 2 degrees of freedom. Sites were identified as
being under positive selection if the computed Bayes empirical Bayes
probability for the site belonging to the positive selection class was >0.95.
Clustering of Sites under Positive Selection. Statistical significance for sites
under positive selection clustering in regions of the SAMHD1 linear sequence
was determined by combinatorial analysis. Briefly, in a sequence of N =
626 sites, of which n are under positive selection, there is a region of bi-
ological interest comprising R sites (R < N), of which r are under positive
selection (r ≤ n). The probability of r or more of the n positively selected sites














Protein Expression and Purification. The DNA sequence for human SAMHD1
(residues M1–M626) was amplified by PCR from plasmid template and
inserted into a pET52b expression vector (Novagen) using ligation in-
dependent cloning to produce an N-terminal StrepII-tag fusion protein.
Point mutations corresponding to the residues found in other species were
introduced into the WT protein construct by using the Quikchange II kit. All
insert sequences were verified by DNA sequencing. Strep-tagged SAMHD1
constructs were expressed in the E. coli strain Rosetta 2 (DE3) grown at 37 °C
with shaking. Protein expression was induced by addition of 0.1 mM iso-
propyl β-D-thiogalactopyranoside (IPTG) to log-phase cultures (A600 = 0.5),
and the cells were incubated for a further 20 h at 18 °C. Cells were harvested
by centrifugation resuspended in 30 mL of lysis buffer [50 mM Tris·HCl pH
7.8, 500 mM NaCl, 4 mM MgCl2, 0.5 mM Tris(2-carboxyethyl)phosphine
(TCEP), 1× EDTA-free mini complete protease inhibitors (Roche), and 0.1 U/mL
Benzonase (Novagen)] per pellet of 1 L of bacterial culture and lysed by
disruption in EmulsiFlex-C5 homogenizer (Avestin). The lysate was cleared by
centrifugation for 1 h at 48,000 × g and 4 °C, then applied to a 10-mL
StrepTactin affinity column (IBA) followed by 600 mL of wash buffer
(50 mM Tris·HCl, pH 7.8, 500 mM NaCl, 4 mM MgCl2, and 0.5 mM TCEP) at
4 °C. Bound proteins were eluted from the column by circulation of 1 mg of
3C protease (GE) in 10 mL of wash buffer over the column in a closed circuit
overnight. The 3C protease was removed by incubation of the eluent with
500 μL of GSH-Sepharose (GE). After centrifugation to remove the resin, the
supernatant was concentrated to 5 mL and applied to a Superdex 200 16/60
(GE) size-exclusion column equilibrated with 10 mM Tris·HCl (pH 7.8),
150 mM NaCl, 4 mM MgCl2, and 0.5 mM TCEP. Peak fractions were con-
centrated to ∼20 mg/mL and flash-frozen in liquid nitrogen in small aliquots.
SEC-MALLS. SEC-MALLS was used to determine themolar mass composition of
SAMHD1 samples upon addition of deoxynucleotide/nucleotide substrates
(dATP; 500 μM) and activators (GTP; 200 μM). Samples (30 μM SAMHD1 and
variants) were incubated with substrate and activator at 4 °C for 5 min, and
then 100 μL was applied to a Superdex 200 10/300 GL column equilibrated in
20 mM Tris·HCl, 150 mM NaCl, 5 mM MgCl2, 0.5 mM TCEP, and 3 mM NaN3
(pH 8.0) at a flow rate of 0.5 mL/min. The scattered light intensity and
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protein concentration of the column eluate were recorded by using a
DAWN-HELEOS laser photometer and an OPTILAB-rEX differential refrac-
tometer (dRI) (dn/dc = 0.186), respectively. The weight-averaged molecular
mass of material contained in chromatographic peaks and peak integrals
were determined by using the combined data from both detectors in the
ASTRA software (Version 6.1; Wyatt Technology Corp.).
SAMHD1 Catalytic Activity Assays. The hydrolysis of dNTPs by SAMHD1 and
SAMHD1 variants was quantified by using a coupled assay utilizing the
biosensor MDCC-PBP (53, 54) to measure phosphate release from combined
SAMHD1 triphosphohydrolase and Saccharomyces cerevisiae Ppx1 exopoly-
phosphatase activity as described (55). In a typical experiment, solutions
containing SAMHD1 constructs, Ppx1, MDCC-PBP, and GTP were incubated
for 5 min in assay buffer (20 mM Tris, pH 8.0, 150 mM NaCl, 5 mMMgCl2, and
2 mM TCEP) at 25 °C before the reaction was initiated by the addition of
substrate [thymidine triphosphate (TTP)]. The final concentrations were
100 nM SAMHD1, 10 nM Ppx1, 40 μM MDCC-PBP, 0.2 mM GTP, and varying
concentration of TTP. The fluorescence intensity was recorded at 430-nm
excitation and 465-nm emission over a period of 10–30 min in a Clariostar
multiwall plate reader (BMG). Steady-state rates were obtained from time
courses of Pi formation by linear regression of the data points in the linear
phase of the reaction. Rates were divided by the SAMHD1 concentration and
plotted versus substrate concentration. Apparent dissociation constants for
substrate binding (KM) and catalytic constants (kcat) were then determined
by nonlinear least-squares fitting using either a hyperbolic or a Hill function.
All measurements were performed in duplicate or triplicate.
SAMHD1 Plasmids. WT SAMHD1 was previously cloned into the pLGate-
wayIeYFP vector to create pLGateway_SAMHD1IRESYFP (23). SAMHD1mutants
(R566Q, A574S, A574L, Q594L, Q594R, K596D, K596P, K596L, and K596M) were
created by PCR-based (Pfu; Agilent) site-directed mutagenesis of the
pLGateway_SAMHD1IRESYFP vector using the manufacturer’s protocol
and the primers listed in SI Appendix, Table S8.
Cells and Virus Production. The 293T cells were maintained in Dulbecco’s
modified Eagle medium (Life Technologies) and U937 cells in RPMI +[L]-
glutamine (Life Technologies), each supplemented with 10% heat-inactivated
fetal bovine serum (Labtech) and 1% penicillin/streptomycin (Sigma). Moloney
murine leukemia virus-based SAMHD1 and yellow fluorescent protein (YFP)-
expressing virus-like particles (VLPs) were produced by cotransfecting 293T cells
with pVSV-G (56), pKB4 (57), and pLGateway_SAMHD1IRESYFP (WT or mutants)
into 293T cells and harvesting 48 h after transfection. HIV-1-GFP was made
by cotransfection of pVSV-G, p8.91 (58), and pCSGWGFP (59). EIAV-GFP
vector was made with plasmids pEIAV-SIN6.1 CGFPW, pEV53D (gift of John
Olsen, Addgene, Chapel Hill, NC; ref. 60), and pVSV-G. FIV-GFP vector was
made by using plasmids pGIN SIN FIVGFP, pFP93 (gift of Eric Poeschla, Uni-
versity of Colorado, Denver), and pVSV-G (61). Plasmids were mixed at ratio
3:3:3 μg/10-cm dish. Supernatants were collected 48 and 72 h post-
transfection, centrifuged at 3,000 rpm, filtered through a 0.45-μm filter, and
concentrated on the same day by centrifugation at 100,000 × g for 2 h at 4 °C
through a 20% sucrose cushion before resuspension in serum-free RPMI. VLPs
were titered on U937 cells for normalization prior to infection. Viral stocks
were stored at −80 °C until use.
HIV-1 Restriction Assay. Undifferentiated U937 cells (3 × 105 cells in 12-well
plate) were transduced with SAMHD1-YFP VLPs by spinoculation at 800 × g
for 90 min in the presence of 10 μg/mL polybrene. After 72 h incubation, the
cells were passaged 1:4 and differentiated with 100 nM phorbol 12-
myristate 13-acetate (Sigma) for 96 h. Differentiated cells were infected in
triplicate with HIV-1-GFP in the presence of 10 μg/mL polybrene, and re-
striction was assessed after 72 h by 2-color flow cytometry using a
Fortessa ×20 analyzer (BD Biosciences). Data were analyzed by using the
FlowJo software suite. Restriction was calculated by dividing the percentage
of SAMHD1-expressing (YFP +ve) cells that were infected with HIV-1 (GFP
+ve) by the percentage of SAMHD1-negative cells that were infected to give
an infection ratio, R.
Immunoblotting. As described above, SAMHD1-YFP–expressing U937 cells
were sorted on MoFlo XDP (Beckman Coulter). After culturing for 3–4 d to
recover from cell sorting, 1 × 107 cells were harvested and washed twice with
phosphate-buffered saline. Supernatant was removed, and cells were lysed
with 100 μg of radioimmunoprecipitation assay buffer (ThermoFisher) in the
presence of protease inhibitors (Roche), DNase (Invitrogen), and phospha-
tase inhibitor (ThermoFisher) at 4 °C for 1 h. The lysates were subsequently
sonicated for 5 min, ×2 pulses, and 40% amplitude and centrifuged for
30 min at 4 °C and 48,000 × g. Laemmli buffer (2×, Sigma) was added at a
1:1 ratio to the lysate and boiled at 95 °C for 5 min. To separate proteins,
samples were loaded on sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis and transferred onto polyvinylidene fluoride membranes (Mil-
lipore), which were then incubated with blocking buffer (5% bovine serum
albumin and 0.05% Tween 20 in Tris·HCl buffer, pH 7.5; Sigma) at 4 °C
overnight. Mouse anti-SAMHD1 1F6 monoclonal antibody (GeneTex; 1:500)
and rabbit anti-phosphorylated-SAMHD1 monoclonal antibody (CST; 1:1,000)
were used as primary antibodies. Corresponding secondary antibodies used
were goat anti-mouse IRDye800CW (LI-COR; 1:10,000) and goat anti-rabbit
IRDye800CW (LI-COR; 1:10,000). Fluorescence was measured by using the LI-COR
Odyssey imaging (LI-COR Bioscience).
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